Dapagliflozin is an oral SGLT2 inhibitor marketed as Farxiga/Forxiga for type 2 diabetes and also used in heart failure and chronic kidney disease populations. It lowers blood glucose by increasing urinary glucose excretion through renal SGLT2 inhibition. It is prescription-only in major markets.
Analysis shows around a third of 54 drugs on TrumpRx.gov are cheaper in the UK, while the platform offers significant savings primarily for obesity and fertility drugs not typically covered by insurance.
New research reveals GLP-1 receptor agonists reduce substance use disorders by 14%, lower Parkinson's disease risk after 5-10 years of use, and cut endometrial cancer risk by 66% when combined with progestin therapy.
Finerenone met its primary endpoint in reducing albuminuria in type 1 diabetic kidney disease, marking the first successful drug trial in 30 years for this population. Separately, SGLT2 inhibitors showed superior kidney protection compared to GLP-1 medications in type 2 diabetes patients.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07547878 |
Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD) |
NOT_YET_RECRUITING | PHASE4 |
| NCT02429258 |
Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or Insulin |
COMPLETED | PHASE4 |
